Axsome Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Axsome Therapeutics

10/08/2026 14:30

Axsome Therapeutics, Inc. AXSM.OQ reported a quarterly adjusted loss of 99 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -97 cents.  The mean expectation of twenty two analysts for the quarter was for a loss of 84 cents per share. Wall Street expected results to range from $-1.25 to -13 cents per share.
Revenue rose 45.5% to $218.38 million from a year ago; analysts expected $221.23 million. 
Axsome Therapeutics, Inc.'s reported EPS for the quarter was a loss of 99 cents​.
The company reported a quarterly loss of $51.31 million.
Axsome Therapeutics, Inc. shares had fallen by 13.1% this quarter and gained 16.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2.5% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Axsome Therapeutics, Inc. is $272.00, about 21.8% above its last closing price of $212.74
This summary was machine generated from LSEG data August 10 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.84
-0.99
Missed
Mar. 31 2026 
-0.90
-1.26
Missed
Dec. 31 2025 
-0.67
-0.56
Beat
Sep. 30 2025 
-0.87
-0.94
Missed